Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis

A phase 1 study of a recombinant mutant protective antigen (rPA) vaccine was conducted in 186 healthy adults aged 18 to 45 years. Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-μg dosages each, or the licensed vaccine,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bellanti, Joseph A., Lin, Feng-Ying C., Chu, Chiayung, Shiloach, Joseph, Leppla, Stephen H., Benavides, German A., Karpas, Arthur, Moayeri, Mahtab, Guo, Chunyan, Robbins, John B., Schneerson, Rachel
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2012
Témata:
Vaccines
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272932/
https://ncbi.nlm.nih.gov/pubmed/22190398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05556-11
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky